Latest Study Shows Signos Drives Up to 7% Weight Loss Over 6 Months, Rivaling Real-World GLP-1 Weight Loss
Signos Inc. announced today results from a real-world study demonstrating that adults with obesity without diabetes who actively engaged with the Signos System – a digital metabolic health platform integrating AI-driven coaching and Dexcom continuous glucose monitoring – achieved greater weight loss than during periods of non-engagement. The results add to the clinical evidence supporting a weight loss indication for the Signos System.
Signos, Inc., Maker of the First FDA-cleared CGM System for Weight Management, Raises $20 Million to Accelerate Growth
Signos Inc., the company behind the first FDA-cleared, over-the-counter glucose monitoring system for weight management, today announced a $20 million funding round with investment from GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. As part of the partnership with Dexcom, Signos will be available for purchase on Stelo.com, Dexcom's direct-to-consumer CGM website, making it easier for people to find and access the Signos system.
